news & resources

publications and posters

Peer-Reviewed Publications

PRV-031 (TEPLIZUMAB)

Hagopian et al. Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes, Diabetes 2013, 62:3901-3908

Sherry et al, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial, Lancet 2011, 378:487-497.

Kuhn and Weiner, Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside, Immunotherapy 2016, 8:889-906

 

PRV-015

Shah S et al., Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014 Sep;109(9):1304-11.

Guandalini S, et al., Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Dig Dis Sci. 2016 Oct;61(10):2823-2830.

Syage JA, et al., Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am J Clin Nutr. 2018 Feb 1;107(2):201-207.

Malamut G, et al., IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. Clin Invest. 2010 Jun;120(6):2131-43.

Ettersperger J, et al., Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016 Sep 20;45(3):610-625.

Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-34.

 

PRV-6527

von Tresckow et al., An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma, Clin Cancer Res. 2015 Apr 15;21(8):1843-50

Franze et al., Interleukin-34 sustains inflammatory pathways in the gut, Clin Sci (Lond). 2015 Aug;129(3):271-80

Genovese et al., Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy, J Rheumatol. 2015 Oct;42(10):1752-60

Marshall et al., Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis. Inflamm Bowel Dis. 2007;13:219-224

Moore B, Liu H, Loza M, et al. Tu2027 Treatment with the CSF-1 Receptor kinase (CSF-1R) Inhibitor JNJ40346527 Suppresses Murine Colitis. Gastroenterology. 2014:146(5): S-900-901.

 

PRV-300

Zhou et al., Recognition of Double-Stranded RNA by TLR3 Induces Severe Small Intestinal Injury in Mice, J Immunol. 2007 Apr 1;178(7):4548-56

Hutchens et al., TLR3 Increases Disease Morbidity and Mortality from Vaccinia Infection, J Immunol. 2008 Jan 1;180(1):483-91

Le Goffic et al., Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells., J Immunol. 2007 Mar 15;178(6):3368-72

Silkoff et al. Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study. J Allergy Clin Immunol. 2018 Apr;141(4):1220-1230

 

PRV-3279

Veri et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 2010 Jul;62(7):1933-43.

Su et al., Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007 Mar 1;178(5):3272-80.

Franks et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec; 43:39-45.

 

PRV-101

Hyöty et al., Developing a vaccine for type 1 diabetes by targeting coxsackievirus B, Expert Rev Vaccines. 2018 Nov 19:1-13

Laitinen et al., Coxsackievirus B1 Is Associated With Induction of beta-Cell Autoimmunity That Portends Type 1 Diabetes, Diabetes. 2014 Feb;63(2):446-55.

Oikarinen et al., Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B1 and Type 1 Diabetes, Diabetes. 2014 Feb;63(2):655-62

Romero. Pediatric Group B Coxsackievirus Infections, Curr Top Microbiol Immunol. 2008; 323:223-39.

Sioofy-Khojine et al., Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes, Diabetologia. 2018 May;61(5):1193-1202

Stone et al., A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes, Diabetologia. 2018 Feb;61(2):476-481